Post Conference Perspective: Immune Checkpoint Inhibitors in Advanced and Metastatic Urothelial Carcinoma

Petros Grivas, MD, PhD, reviews data from recent subgroup analyses for the JAVELIN Bladder 100 study for advanced urothelial carcinoma from the 2021 ASCO GU Virtual Symposium.

Considerations for approaching avelumab switch maintenance after frontline chemotherapy response and data from the 2021 ASCO GU Virtual Symposium on ICI maintenance therapy in metastatic urothelial carcinoma.

Petros Grivas, MD, PhD, comments on the value of switch maintenance immunotherapy, as seen in the JAVELIN Bladder 100 trial, for the management of urothelial carcinoma.

Petros Grivas, MD, PhD, discusses the role of concurrent immune checkpoint inhibition plus chemotherapy in first-line metastatic urothelial carcinoma and comments on the ongoing phase 3 NILE, CheckMate 901, and EV-3O2 studies.

Factors influencing the sequencing of ICI (Immune checkpoint inhibitors) therapy in the second-line setting for urothelial carcinoma.

A review of the KEYNOTE-361 study and recent findings of the post-hoc analysis looking at long-term results of pembrolizumab vs chemotherapy as first-line treatment for advanced urothelial carcinoma.

Petros Grivas, MD, PhD, discusses exciting findings and impactful data from the 2021 ASCO GU Virtual Symposium for the treatment of urothelial carcinoma.

Petros Grivas, MD, PhD, shares his thoughts on the future of maintenance therapy in locally advanced or metastatic urothelial carcinoma.